These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Sonidegib: A Review in Locally Advanced Basal Cell Carcinoma. Burness CB; Scott LJ Target Oncol; 2016 Apr; 11(2):239-46. PubMed ID: 26867946 [TBL] [Abstract][Full Text] [Related]
11. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439 [TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma. Collier NJ; Ali FR; Lear JT Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497 [TBL] [Abstract][Full Text] [Related]
14. Exposure-Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors. Zhou J; Quinlan M; Hurh E; Sellami D J Clin Pharmacol; 2016 Nov; 56(11):1406-1415. PubMed ID: 27095306 [TBL] [Abstract][Full Text] [Related]
15. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Fassnacht M; Berruti A; Baudin E; Demeure MJ; Gilbert J; Haak H; Kroiss M; Quinn DI; Hesseltine E; Ronchi CL; Terzolo M; Choueiri TK; Poondru S; Fleege T; Rorig R; Chen J; Stephens AW; Worden F; Hammer GD Lancet Oncol; 2015 Apr; 16(4):426-35. PubMed ID: 25795408 [TBL] [Abstract][Full Text] [Related]
17. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627 [TBL] [Abstract][Full Text] [Related]
18. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Chen L; Silapunt S; Migden MR Future Oncol; 2016 Sep; 12(18):2095-105. PubMed ID: 27189494 [TBL] [Abstract][Full Text] [Related]
19. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma. Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567 [TBL] [Abstract][Full Text] [Related]